CME Satellite Symposium

A CME Satellite Symposium during The Liver Meeting® 2026 of the American Association for the Study of Liver Diseases (AASLD) in Denver, Colorado.

Lunch and Symposium: 12:00–1:30 PM MT

AGENDA

12:00 PM            Introduction
                           Arun Sanyal, MD (Chair)

12:05 PM            From Metabolic Risk to Fibrosis Stage – Implementing the NIT Framework in Hepatology Practice
                           Mary Rinella, MD

12:25 PM            Resmetirom and Semaglutide in Clinical Practice
                           Rohit Loomba, MD, MHSc

12:45 PM            The FGF21 Analog Class – Mechanism, Evidence, and the Compensated Cirrhosis Challenge
                           Mazen Noureddin, MD, MHSc

1:05 PM              Case Discussions
                           Presenter: Arun Sanyal, MD
                           Panelists: Rohit Loomba, MD, MHSc; Mazen Noureddin, MD, MHSc; Mary Rinella, MD

1:20 PM              Question and Answer

EDUCATIONAL OBJECTIVES

■ Apply the AASLD-endorsed stepwise non-invasive testing framework — including FIB-4, VCTE/ELF, and MRE — to identify patients with MASH and significant fibrosis (F2–F3) who are candidates for pharmacotherapy, and describe the role of liver biopsy in cases of diagnostic uncertainty
■ Compare the mechanism of action, Phase 3 clinical evidence, patient selection criteria, and monitoring requirements for resmetirom and semaglutide 2.4 mg/week in patients with non-cirrhotic MASH and F2–F3 fibrosis, and apply this comparison to individualized treatment decisions based on patient comorbidity profile
■ Characterize the FGF21 analog class — including efruxifermin and pegozafermin — by mechanism of action, Phase 2 and Phase 3 evidence to date, and current regulatory status, and describe the evidence supporting the investigational role of FGF21 analogs in patients with pre-cirrhotic MASH and compensated cirrhosis due to MASH
■ Formulate an evidence-based management plan for patients with compensated MASH cirrhosis, including surveillance priorities, appropriate use of approved therapies for comorbid conditions, and accurate patient communication regarding investigational treatment options

TARGET AUDIENCE

This program is targeted to hepatologists and gastroenterologists and other advanced practice providers practicing in hepatology and gastroenterology.

ACCREDITATION AND CREDIT DESIGNATION

Voxmedia, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Grant

Voxmedia International gratefully acknowledges the educational grant provided by Novo Nordisk Inc.

CHAIR

Arun Sanyal, MD
Chief, Division of Gastroenterology, Hepatology, and Nutrition
Professor of Medicine, Physiology and Molecular Pathology
Virginia Commonwealth University School of Medicine
Richmond, Virginia

FACULTY

Rohit Loomba, MD, MHSc
Chief, Division of Gastroenterology and Hepatology
Director, UC San Diego MASLD Research Center
Professor of Medicine
UC San Diego Health
San Diego, California

Mazen Noureddin, MD, MHSc
Professor of Medicine
Sherry and Alan Conover Center for Liver Disease & Transplantation
Underwood Center for Digestive Health
J.C. Walter Jr. Transplant Center
Houston Methodist
Houston, Texas

Mary Rinella, MD
Professor of Medicine
Director, Metabolic and Fatty Liver Disease
The University of Chicago Medicine
Chicago, Illinois

This event is provided by Voxmedia LLC and supported by Novo Nordisk. This is not an official event/function of the American Association for the Study of Liver Diseases.